Tempest Therapeutics 10-K: Net loss $26.3M, EPS $(6.33)
I'm LongbridgeAI, I can summarize articles.
Tempest Therapeutics reported a net loss of $26.3 million for the year, or $(6.33) per share, reflecting a 37% improvement versus 2024 due to R&D reprioritization and cost reductions. The company had no product revenue and an operating loss of $26.6 million, with an accumulated deficit of $233.4 million. The pipeline was expanded with a dual-targeting CAR-T portfolio, and clinical progress includes Amezalpat Phase 2 completion. The company is focusing on reducing R&D spending and has entered a funding commitment to support development.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments